{"title": "Eficacia y seguridad de cuatro COVID-19 vacunas para prevenir la infecci\u00f3n por SARS-CoV-2: una revisi\u00f3n r\u00e1pida", "author": "Lina Sof\u00eda Mor\u00f3n-Duarte; Kelly Roc\u00edo Chac\u00f3n; Mar\u00eda Paula Guti\u00e9rrez; Ilich Herbert De La Hoz; Nancy Yomayusa", "url": null, "hostname": null, "description": "Introduction: Since the emergence of the SARS-CoV-2, there have been efforts to develop vaccines to control the COVID-19 pandemic.Objective: The present study assessed the efficacy and safety of the BNT162b2, mRNA-1273, ChAdOx1/AZD1222 and Gam-COVID-Vac rAd26-S/rAd5-S vaccines against theSARS-CoV-2.Materials and methods: We searched PubMed/MEDLINE, Google Scholar, Cochrane, and the WHO International Clinical Trials Registry Platform on March 15, 2021. The searchterms used were: \u201cvaccine\u201d OR \u201cvaccination\u201d AND \u201ccovid19\u201d OR \u201ccoronavirus\u201d OR \u201csarscov2\u201d AND \u201cbnt162b2\u201d OR \u201cchadox1-S\u201d OR \u201cazd1222\u201d OR \u201csputnik\u201d OR \u201cGam-COVID-Vac\u201d OR\u201cmrna\u201d OR \u201cmRNA-1273\u201d . We measured the risk of bias of the studies and the quality of the evidence using GRADE profiles. A qualitative and quantitative analysis of the results of clinical trials is presented.Results: Of the 74 identified studies, 4 were finally included in this review. The efficacies of the BNT162b2, mRNA-1273, ChAdOx1/AZD1222 and Gam-COVID-VacrAd26-S/rAd5-S vaccines against symptomatic COVID-19 were 95,0% (CI95% 90,3-97,6), 94,1% (CI95% 89,3-96,8), 66,7% (CI95% 57,4-74,0), and 91,1% (CI95% 83,8-95,1), respectively. There was moderate certainty of the evidence due to serious indirectness, when we measured the risk of bias of the studies and the quality of the evidence using GRADE profile. The safety profiles were acceptable, and data on serious adverse events (summary RR=0,93; CI95% 0,77-1,12; p=0,16) and deaths from all causes (summary RR=0,70; CI95% 0,33-1,50; p=0,90) showed no significant differences.Conclusion: The results of this review support the level of evidence for the efficacy and safety of the COVID-19 vaccines analysed.", "sitename": "Biom\u00e9dica", "date": "2022-10-31", "id": null, "license": "CC BY 4.0", "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Eficacia y seguridad de cuatro COVID-19 vacunas para prevenir la infecci\u00f3n por SARS-CoV-2: una revisi\u00f3n r\u00e1pida\nResumen\nIntroducci\u00f3n. Desde que surgi\u00f3 el virus SARS-CoV-2, se han realizado esfuerzos para desarrollar vacunas para controlar la pandemia por COVID-19.\nObjetivo. Evaluar los datos de la eficacia y seguridad de las vacunas BNT162b2, mRNA-1273, ChAdOx1/AZD1222 y Gam-COVID-Vac rAd26-S/rAd5-S contra el SARS-CoV-2.\nMateriales y m\u00e9todos. Se realizaron b\u00fasquedas en PubMed/MEDLINE, Google Scholar, Cochrane y la Plataforma de Registro Internacional de Ensayos Cl\u00ednicos de la OMS el 15 de marzo de 2021. Los t\u00e9rminos usados fueron: \u201cvaccine\u201d OR \u201cvaccination\u201d AND \u201ccovid19\u201d OR \u201ccoronavirus\u201d OR \u201csarscov2\u201d AND \u201cbnt162b2\u201d OR \u201cchadox1-S\u201d OR \u201cazd1222\u201d\nOR \u201csputnik\u201d OR \u201cGam-COVID-Vac\u201d OR \u201cmrna\u201d OR \u201cmRNA-1273\u201d. Se midi\u00f3 el riesgo de sesgo de los estudios y la calidad de la informaci\u00f3n por medio de los perfiles GRADE. Se presenta un an\u00e1lisis cualitativo y cuantitativo de los resultados de los estudios cl\u00ednicos.\nResultados. Se identificaron 74 estudios y se incluyeron 4 en la revisi\u00f3n. La eficacia de las vacunas BNT162b2, mRNA-1273, ChAdOx1/AZD1222 y Gam-COVID-VacrAd26-S/rAd5-S contra la COVID-19 sintom\u00e1tica fue del 95,0 % (IC95% 90,3-97,6), 94,1 % (IC95% 89,3-96,8), 66,7 % (IC95% 57,4-74,0) y 91,1 % (IC95% 83,8-95,1), respectivamente, y hubo una certeza moderada de la informaci\u00f3n debido a la falta de evidencia directa. Los perfiles de seguridad fueron aceptables, y los eventos adversos graves (RR resumido=0,93; IC95% 0,77-1,12; p=0,16) y muerte por todas las causas (RR resumido=0,70; IC95% 0,33-1,50; p=0,90) no mostraron diferencias significativas.\nConclusi\u00f3n. Los resultados de esta revisi\u00f3n respaldan el nivel de evidencia de la eficacia y seguridad de las vacunas COVID-19 que fueron analizadas.\nDescargas\nReferencias bibliogr\u00e1ficas\nWu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265-69.\n[https://doi.org/10.1038/s41586-020-2008-3](https://doi.org/10.1038/s41586-020-2008-3)\nGorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;4:536-44.\n[https://doi.org/10.1038/s41564-020-0695-z](https://doi.org/10.1038/s41564-020-0695-z)\nWorld Health Organization. Coronavirus disease (COVID-19) pandemic, dashboard. Accessed: June 21, 2021. Available at:\n[https://covid19.who.int/](https://covid19.who.int/)\nSchuchat A. Human vaccines and their importance to public health. Procedia in Vaccinology. 2011;5:120-6.\n[https://doi.org/10.1016/j.provac.2011.10.008](https://doi.org/10.1016/j.provac.2011.10.008)\nClinicalTrials.gov. COVID, SARS-CoV-2, Vaccination. Accessed: June 21, 2021. Available at:\n[https://clinicaltrials.gov/ct2/results?cond=Covid19&term=vaccines&cntry=&state=&city=&dist=](https://clinicaltrials.gov/ct2/results?cond=Covid19&term=vaccines&cntry=&state=&city=&dist=)\nWorld Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines. Accessed: June 21, 2021. Available at:\n[https://www.who.int/publications/m/item/draftlandscape-of-covid-19-candidate-vaccines](https://www.who.int/publications/m/item/draftlandscape-of-covid-19-candidate-vaccines)\nHaghpanah F, Lin G, Levin SA, Klein E. Analysis of the potential impact of durability, timing, and transmission blocking of COVID-19 vaccine on morbidity and mortality. EClinicalMedicine. 2021;35:1-13.\n[https://doi.org/10.1016/j.eclinm.2021.100863](https://doi.org/10.1016/j.eclinm.2021.100863)\nFood and Drug Administration. Moderna COVID-19 Vaccine, Emergency Use Authorization (EUA) of the Moderna covid-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Accessed: April 21, 2021. Available at:\n[https://www.fda.gov/emergency-preparedness-andresponse/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine](https://www.fda.gov/emergency-preparedness-andresponse/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine)\nFood and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine. Accessed: April 21, 2021. Available at:\n[https://www.fda.gov/emergency-preparedness-andresponse/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine](https://www.fda.gov/emergency-preparedness-andresponse/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine)\nAztraZeneca. AstraZeneca\u2019s COVID-19 vaccine authorised for emergency supply in the UK. Accessed: April 21, 2021. Available at:\n[https://www.astrazeneca.com/media-centre/pressreleases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html](https://www.astrazeneca.com/media-centre/pressreleases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html)\nWorld Health Organization. Pfizer/BioNTech COMIRNATY\u00ae, COVID-19 vaccine. Accessed: April 22, 2021. Available at:\n[https://www.who.int/publications/m/item/comirnaty-covid-19-mrna-vaccine](https://www.who.int/publications/m/item/comirnaty-covid-19-mrna-vaccine)\nPage MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.\n[https://doi.org/10.1136/bmj.n71](https://doi.org/10.1136/bmj.n71)\nHiggins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.\n[https://doi.org/10.1136/bmj.d5928](https://doi.org/10.1136/bmj.d5928)\nSantesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26: Informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126-35.\n[https://doi.org/10.1016/j.jclinepi.2019.10.014](https://doi.org/10.1016/j.jclinepi.2019.10.014)\nLangan D, Higgins JPT, Simmonds M. Comparative performance of heterogeneity variance estimators in meta-analysis: A review of simulation studies. Res Synth Methods. 2017;2:181-98.\n[https://doi.org/10.1002/jrsm.1198](https://doi.org/10.1002/jrsm.1198)\nHiggins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;11:1539-58.\n[https://doi.org/10.1002/sim.1186](https://doi.org/10.1002/sim.1186)\nWalsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;25:2439-50.\n[https://doi.org/10.1056/NEJMoa2027906](https://doi.org/10.1056/NEJMoa2027906)\nEwer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) Vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27:270-8.\n[https://doi.org/10.1038/s41591-020-01194-5](https://doi.org/10.1038/s41591-020-01194-5)\nMulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;7830:589-93.\n[https://doi.org/10.1038/s41586-020-2639-4](https://doi.org/10.1038/s41586-020-2639-4)\nFolegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;10249:467-78.\n[https://doi.org/10.1016/S0140-6736(20)31604-4](https://doi.org/10.1016/S0140-6736(20)31604-4)\nBarrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;2:279-88.\n[https://doi.org/10.1038/s41591-020-01179-4](https://doi.org/10.1038/s41591-020-01179-4)\nRamasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;10267:1979-93.\n[https://doi.org/10.1016/S0140-6736(20)32466-1](https://doi.org/10.1016/S0140-6736(20)32466-1)\nKeech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARSCoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;24:2320-32.\n[https://doi.org/10.1056/NEJMoa2026920](https://doi.org/10.1056/NEJMoa2026920)\nPolack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;27:2603-15.\n[https://doi.org/10.1056/NEJMoa2034577](https://doi.org/10.1056/NEJMoa2034577)\nBaden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-16.\n[https://doi.org/10.1056/NEJMoa2035389](https://doi.org/10.1056/NEJMoa2035389)\nVoysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;10269:99-111.\n[https://doi.org/10.1016/S0140-6736(20)32661-1](https://doi.org/10.1016/S0140-6736(20)32661-1)\nVoysey M, Costa-Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Singledose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet. 2021;10277:881-91.\n[https://doi.org/10.1016/S0140-6736(21)00432-3](https://doi.org/10.1016/S0140-6736(21)00432-3)\nLogunov DY, Dolzhikova I V, Shcheblyakov D V, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;10275:671-81.\n[https://doi.org/10.1016/S0140-6736(21)00234-8](https://doi.org/10.1016/S0140-6736(21)00234-8)\nCenters for Disease Control and Prevention. Science Brief: Background rationale and evidence for public health recommendations for fully vaccinated people. Accessed: April 22, 2021. Available at:\n[https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fullyvaccinated-people.html](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fullyvaccinated-people.html)\nWorld Health Organization. Target product profiles for COVID-19 vaccines. Accessed: May 10, 2021. Available at:\n[https://www.who.int/publications/m/item/who-target-product-profiles-forcovid-19-vaccines](https://www.who.int/publications/m/item/who-target-product-profiles-forcovid-19-vaccines)\nWorld Health Organization. WHO issues it\u2019s first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access. Accessed: April 10, 2021. Available at:\n[https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-usevalidation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access](https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-usevalidation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access)\nSinopharm. Chinese Covid-19 vaccine efficacy better than expected. Accessed: April 10, 2021. Available at:\n[https://www.precisionvaccinations.com/vaccines/sinopharm-covid-19-vaccine-bbibp-corv](https://www.precisionvaccinations.com/vaccines/sinopharm-covid-19-vaccine-bbibp-corv)\nMallapaty S. China COVID vaccine reports mixed results \u2014 what does that mean for the pandemic? Accessed: April 10, 2021. Available at:\n[https://www.nature.com/articles/d41586-021-00094-z](https://www.nature.com/articles/d41586-021-00094-z)\nCenters for Disease Control and Prevention. Johnson & Johnson\u2019s Janssen COVID-19 vaccine overview and safety. Accessed: May 10, 2021. Available at:\n[https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html)\nFood and Drug Administration. FDA issues emergency use authorization for third COVID-19 vaccine. Accessed: May 10, 2021. Available at:\n[https://www.fda.gov/news-events/pressannouncements/fda-issues-emergency-use-authorization-third-covid-19-vaccine](https://www.fda.gov/news-events/pressannouncements/fda-issues-emergency-use-authorization-third-covid-19-vaccine)\nGrant MJ, Booth A. A typology of reviews: An analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;2:91-108.\n[https://doi.org/10.1111/j.1471-1842.2009.00848.x](https://doi.org/10.1111/j.1471-1842.2009.00848.x)\nTricco AC, Antony J, Zarin W, Strifler L, Ghassemi M, Ivory J, et al. A scoping review of rapid review methods. BMC Med. 2015;13:224.\n[https://doi.org/10.1186/s12916-015-0465-6](https://doi.org/10.1186/s12916-015-0465-6)\nAlberta Health Services. COVID-19 Scientific Advisory Group evidence summary and recommendations. Accessed: May 10, 2021. Available at:\n[https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-post-vaccine-transmission-rapid-review.pdf](https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-post-vaccine-transmission-rapid-review.pdf)\nCenters for Disease Control and Prevention. CDC issues first set of guidelines on how fully vaccinated people can visit safely with others. Accessed: May 10, 2021. Available at:\n[https://www.cdc.gov/media/releases/2021/p0308-vaccinated-guidelines.html](https://www.cdc.gov/media/releases/2021/p0308-vaccinated-guidelines.html)\nDerechos de autor 2022 Biom\u00e9dica\nEsta obra est\u00e1 bajo una licencia internacional\n[Creative Commons Atribuci\u00f3n 4.0](https://creativecommons.org/licenses/by/4.0/).\n|Estad\u00edsticas de art\u00edculo|\n|Vistas de res\u00famenes|\n|Vistas de PDF|\n|Descargas de PDF|\n|Vistas de HTML|\n|Otras vistas|\n1. Kontovazainitis, Christos-Georgios , Katsaras, Georgios N. , Gialamprinou, Dimitra , Mitsiakos, Georgios , Covid-19 vaccination and pregnancy: a systematic review of maternal and neonatal outcomes, 2023.", "language": null, "image": null, "pagetype": null, "links": ["#pkp_content_main", "#pkp_content_nav", "#pkp_content_footer", "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\thttps://revistabiomedica.org/index.php/index\n\t\t\t\t\t\t\t\t\t\t\t\t\t", "https://www.ins.gov.co/", "https://www.revistabiomedica.org/index.php/biomedica", "https://revistabiomedica.org/index.php/biomedica/publianticipada", "https://revistabiomedica.org/index.php/biomedica/issue/current", "https://revistabiomedica.org/index.php/biomedica/issue/archive", "https://revistabiomedica.org/index.php/biomedica/announcement", "https://revistabiomedica.org/index.php/biomedica/about", "https://revistabiomedica.org/index.php/biomedica/about", "https://revistabiomedica.org/index.php/biomedica/about/submissions", "https://revistabiomedica.org/index.php/biomedica/about/editorialTeam", "https://revistabiomedica.org/index.php/biomedica/about/privacy", "https://revistabiomedica.org/index.php/biomedica/about/contact", "https://revistabiomedica.org/index.php/biomedica/search/search", "#", "https://www.revistabiomedica.org/index.php/biomedica/user/setLocale/es_ES?source={$smarty.server.REQUEST_URI}", "https://www.revistabiomedica.org/index.php/biomedica/user/setLocale/en_US?source={$smarty.server.REQUEST_URI}", "https://revistabiomedica.org/index.php/biomedica/user/register", "https://revistabiomedica.org/index.php/biomedica/login", "https://revistabiomedica.org/index.php/biomedica/index", "https://revistabiomedica.org/index.php/biomedica/issue/archive", "https://revistabiomedica.org/index.php/biomedica/issue/view/190", "https://doi.org/10.7705/biomedica.6254", "#resumen", "#author", ".downloads_chart", "#references", "#citations", "https://orcid.org/0000-0002-5044-7252", "https://orcid.org/0000-0003-4843-7036", "https://orcid.org/0000-0002-3476-4450", "https://orcid.org/0000-0003-4720-6885", "https://orcid.org/0000-0003-2886-8146", "https://doi.org/10.1038/s41586-020-2008-3", "https://doi.org/10.1038/s41564-020-0695-z", "https://covid19.who.int/", "https://doi.org/10.1016/j.provac.2011.10.008", "https://clinicaltrials.gov/ct2/results?cond=Covid19&term=vaccines&cntry=&state=&city=&dist=", "https://www.who.int/publications/m/item/draftlandscape-of-covid-19-candidate-vaccines", "https://doi.org/10.1016/j.eclinm.2021.100863", "https://www.fda.gov/emergency-preparedness-andresponse/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine", "https://www.fda.gov/emergency-preparedness-andresponse/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine", "https://www.astrazeneca.com/media-centre/pressreleases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html", "https://www.who.int/publications/m/item/comirnaty-covid-19-mrna-vaccine", "https://doi.org/10.1136/bmj.n71", "https://doi.org/10.1136/bmj.d5928", "https://doi.org/10.1016/j.jclinepi.2019.10.014", "https://doi.org/10.1002/jrsm.1198", "https://doi.org/10.1002/sim.1186", "https://doi.org/10.1056/NEJMoa2027906", "https://doi.org/10.1038/s41591-020-01194-5", "https://doi.org/10.1038/s41586-020-2639-4", "https://doi.org/10.1016/S0140-6736(20)31604-4", "https://doi.org/10.1038/s41591-020-01179-4", "https://doi.org/10.1016/S0140-6736(20)32466-1", "https://doi.org/10.1056/NEJMoa2026920", "https://doi.org/10.1056/NEJMoa2034577", "https://doi.org/10.1056/NEJMoa2035389", "https://doi.org/10.1016/S0140-6736(20)32661-1", "https://doi.org/10.1016/S0140-6736(21)00432-3", "https://doi.org/10.1016/S0140-6736(21)00234-8", "https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fullyvaccinated-people.html", "https://www.who.int/publications/m/item/who-target-product-profiles-forcovid-19-vaccines", "https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-usevalidation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access", "https://www.precisionvaccinations.com/vaccines/sinopharm-covid-19-vaccine-bbibp-corv", "https://www.nature.com/articles/d41586-021-00094-z", "https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html", "https://www.fda.gov/news-events/pressannouncements/fda-issues-emergency-use-authorization-third-covid-19-vaccine", "https://doi.org/10.1111/j.1471-1842.2009.00848.x", "https://doi.org/10.1186/s12916-015-0465-6", "https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-post-vaccine-transmission-rapid-review.pdf", "https://www.cdc.gov/media/releases/2021/p0308-vaccinated-guidelines.html", "https://revistabiomedica.org/index.php/biomedica/citationstylelanguage/get/apa?submissionId=6254&publicationId=5027", "https://revistabiomedica.org/index.php/biomedica/citationstylelanguage/get/vancouver?submissionId=6254&publicationId=5027", "https://revistabiomedica.org/index.php/biomedica/citationstylelanguage/download/ris?submissionId=6254&publicationId=5027", "https://revistabiomedica.org/index.php/biomedica/citationstylelanguage/download/bibtex?submissionId=6254&publicationId=5027", "https://revistabiomedica.org/index.php/biomedica/article/view/6254/5169", "https://revistabiomedica.org/index.php/biomedica/article/view/6254/5182", "https://revistabiomedica.org/index.php/biomedica/article/view/6254/5170", "https://revistabiomedica.org/index.php/biomedica/issue/view/190", "https://creativecommons.org/licenses/by/4.0/", "https://creativecommons.org/licenses/by/4.0/", "https://plu.mx/plum/a/?doi=10.7705/biomedica.6254", null, null, null, null, null, null, null, "https://doi.org/10.1515/jpm-2022-0463", "https://www.revistabiomedica.org/index.php/biomedica/proceso", "/index.php/biomedica/about/submissions", "https://revistabiomedica.org/index.php/biomedica/submission/wizard", "/index.php/biomedica/tutoriales", "/index.php/biomedica/faq", "https://play.google.com/store/apps/details?id=com.biteca.biomedica", "https://itunes.apple.com/us/app/biomedica/id1073929569", "https://www.facebook.com/RevistaBiomedicaINS/", "https://twitter.com/Biomedica_INS?ref_src=twsrc%5Etfw", "https://linkedin.com/company/biomedica-revista-del-instituto-nacional-de-salud", "https://www.instagram.com/revistabiomedica/", "https://www.ncbi.nlm.nih.gov/pubmed?term=%22Biomedica%22%5BJournal%5D", "https://www.ncbi.nlm.nih.gov/pmc/journals/3871/", "https://login.webofknowledge.com/error/Error?Error=IPError&PathInfo=%2F&RouterURL=https%3A%2F%2Fwww.webofknowledge.com%2F&Domain=.webofknowledge.com&Src=IP&Alias=WOK5", "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local&v1=1&ti=1,1&Search_Arg=8205605&Search_Code=0359&CNT=20&SID=1", "https://www.scimagojr.com/journalsearch.php?q=77291&tip=sid&clean=0", "http://www.scielo.org.co/scielo.php?script=sci_serial&pid=0120-4157&lng=es&nrm=iso", "http://www.redalyc.org/revista.oa?id=843", "https://redib.org/recursos/Serials/Record/oai_revista507", "/index.php/biomedica/es", "/index.php/biomedica/es", "https://revistabiomedica.org/index.php/biomedica/user/setLocale/en_US?source=%2Findex.php%2Fbiomedica%2Farticle%2Fview%2F6254", "https://revistabiomedica.org/index.php/biomedica/user/setLocale/es_ES?source=%2Findex.php%2Fbiomedica%2Farticle%2Fview%2F6254", "https://revistabiomedica.org/index.php/biomedica/gateway/plugin/WebFeedGatewayPlugin/atom", "https://revistabiomedica.org/index.php/biomedica/gateway/plugin/WebFeedGatewayPlugin/rss2", "https://revistabiomedica.org/index.php/biomedica/gateway/plugin/WebFeedGatewayPlugin/rss", "http://www.scielo.org.co", "http://redalyc.uaemex.mx/", "http://pubmed.gov", "https://redib.org/recursos/Record/oai_revista507-biom%C3%A9dica-revista-instituto-nacional-salud", "/index.php/biomedica/pages/view/team", "https://www.facebook.com/RevistaBiomedicaINS", "https://twitter.com/Biomedica_INS", "https://twitter.com/Biomedica_INS?ref_src=twsrc%5Etfw", "https://revistabiomedica.org/index.php/biomedica/submission/wizard", "https://www.revistabiomedica.org/index.php/biomedica/libraryFiles/downloadPublic/6", "/index.php/biomedica/libraryFiles/downloadPublic/30", "/index.php/biomedica/libraryFiles/downloadPublic/28", "/index.php/biomedica/libraryFiles/downloadPublic/29", null, "https://www.ins.gov.co/", "https://doi.org/10.7705/issn.0120-4157", "mailto:biomedica@ins.gov.co", "https://www.revistabiomedica.org/index.php/biomedica/about/aboutThisPublishingSystem", "https://www.biteca.com", "https://revistabiomedica.org/index.php/biomedica/about/aboutThisPublishingSystem"]}